To this aim, it would be recommended to use MET moAbs or tyrosine kinase inhibitors (TKIs) for cancers positive for the full-length receptor, and TKIs or a combination of both for MET-EC- cancers [42,47] (Figure 3). This evidence concerns the gene MET and cancer.